Gsk annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gsk Return on Equity (ROE) Growth & History (GSK)
Gsk's return on equity was 41.86% for fiscal 2025.
View full Gsk company overviewGsk annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 41.86% | +20.01 pp |
| 2024 | 2024-12-31 | 21.84% | −22.49 pp |
| 2023 | 2023-12-31 | 44.33% | −77.45 pp |
| 2022 | 2022-12-31 | 121.79% | +87.40 pp |
| 2021 | 2021-12-31 | 34.38% | −14.77 pp |
| 2020 | 2020-12-31 | 49.15% | −20.23 pp |
| 2019 | 2019-12-31 | 69.38% | −148.56 pp |
| 2018 | 2018-12-31 | 217.94% | −192.86 pp |
| 2017 | 2017-12-31 | 410.80% | +389.56 pp |
| 2016 | 2016-12-31 | 21.24% | — |
Gsk quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.45% | −7.69 pp |
| Q1 2026 | 2026-03-31 | 10.15% | — |
| Q4 2025 | 2025-12-31 | 3.91% | — |
| Q3 2025 | 2025-09-30 | 13.01% | — |
| Q2 2025 | 2025-06-30 | 10.14% | — |
Gsk return on equity trends
Over the last five fiscal years, Gsk's return on equity decreased from 49.15% to 41.86%, a change of −7.29 percentage points. The latest reported quarter, Q2 2026, shows 2.45%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gsk source filings ↗